HLB Therapeutics Co.,Ltd.
KOE: 115450.KQ0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ki Hong Ahn
- Employees
- 93
- Headquarters
- Seongnam, South Korea
- IPO year
- 2010
- Market cap
- ₩293.6B
- Website
- https://hlbtherapeutics.co.kr
Loading 115450…
Loading profile data…Frequently asked questions about 115450
What does HLB Therapeutics Co.,Ltd. (115450.KQ) do?
HLB Therapeutics Co.,Ltd., a biotech company, develops pharmaceutical products in South Korea and internationally. It is developing GBT-201 using Thymosin beta for the treatment of ophthalmic diseases, such as dry eye syndrome and neurotrophic keratopathy; and OKN-007 for the treatment of glioblastoma brain tumor. It is also involved in the whol...
Where does 115450.KQ trade?
HLB Therapeutics Co.,Ltd. (115450.KQ) trades on the KOSDAQ.
What sector is 115450.KQ in?
HLB Therapeutics Co.,Ltd. (115450.KQ) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of HLB Therapeutics Co.,Ltd.?
Ki Hong Ahn is the chief executive officer of HLB Therapeutics Co.,Ltd. (115450.KQ).
Where is HLB Therapeutics Co.,Ltd. headquartered?
HLB Therapeutics Co.,Ltd. is headquartered in South Korea.
Does 115450.KQ pay a dividend?
HLB Therapeutics Co.,Ltd. (115450.KQ) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 115450.KQ go public?
HLB Therapeutics Co.,Ltd. (115450.KQ) completed its initial public offering in 2010.